• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

ASCO: Merck KGaA, Pfizer's Bavencio combo misses survival mark in crowded kidney...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 23, 2024 at 10:22: PM
via Five years after scoring an FDA approval to treat newly diagnosed advanced kidney cancer, the combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta has failed on the overall survival endpoint of a phase 3 trial.

article source
 




Top Bottom
Back
Quote